The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome

Zhang, Xiangyu; Zeng, Xiaofang; Dong, Lini; Zhao, Xiaokun; Qu, Xun

doi:10.1007/s00345-015-1550-3

Cited by 32 publications

(28 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study group also reported similar results using the National Health Information Database of the National Health Insurance Service in South Korea 10 . Moreover, our study group also reported that, among the components of MetS, a decreased high‐density lipoprotein (HDL) cholesterol level was the most powerful variable associated with an increased prevalence of BPH, 10 which was consistent with the findings of previous studies 11,12 . On the basis of these studies, we hypothesized that, like HDL less than 40 mg/dL or dyslipidemia medication, HDL greater than 40 mg/dL might also be associated with a decreased incidence of BPH.…”

Section: Introductionsupporting

confidence: 89%

“…10 Moreover, our study group also reported that, among the components of MetS, a decreased high-density lipoprotein (HDL) cholesterol level was the most powerful variable associated with an increased prevalence of BPH, 10 which was consistent with the findings of previous studies. 11,12 On the basis of these studies, we hypothesized that, like HDL less than 40 mg/dL or dyslipidemia medication, HDL greater than 40 mg/dL might also be associated with a decreased incidence of BPH. In other words, there might be an inverse linear association between HDL cholesterol levels and BPH incidence.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Optimal high‐density lipoprotein cholesterol level for decreasing benign prostatic hyperplasia in men not taking statin medication: A historical cohort study

Yoo

Suh

et al. 2020

The Prostate

View full text Add to dashboard Cite

Background We evaluated the optimal high‐density lipoprotein cholesterol level for benign prostatic hyperplasia (BPH) prevention in men not taking statin medication using a large historical cohort. Methods We initially selected 130 454 men who underwent health checkups in 2009 from the National Health Information Database of the National Health Insurance Service. After excluding 36 854 men with BPH in 2009, and 45 061 men for statin use, 48 539 men were ultimately included in the analysis. A Kaplan‐Meier analysis and multivariable Cox regression analysis was performed to assess the optimal high‐density lipoprotein cholesterol level for preventing BPH. Results High‐density lipoprotein cholesterol levels were less than 40 mg/dL in 7431 (15.3%) men, 40 to 49 in 15 861 (32.7%), 50 to 59 in 15 328 (27.5%), and greater than or equal to 60 in 11 919 (24.6%). The overall cumulative incidence of BPH was 4.4%, 8.7%, 13.0%, and 17.8% at the 1‐, 2‐, 3‐, and 4‐year follow‐up periods, respectively. In multivariable analysis, high‐density lipoprotein greater than or equal to 60 mg/dL were significantly associated with a decreased incidence of BPH, as were age, residence, income, body mass index, diabetes, hypertension, triglyceride, and increased annual clinic visits, especially in men in their 40s. Conclusion Elevated serum high‐density lipoprotein cholesterol levels were negatively associated with BPH incidence. In addition, maintaining high‐density lipoprotein greater than or equal to 60 mg/dL was associated with a decreased BPH incidence compared with high‐density lipoprotein less than 40 mg/dL, especially in men in their 40s.

show abstract

Section: Introductionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Optimal high‐density lipoprotein cholesterol level for decreasing benign prostatic hyperplasia in men not taking statin medication: A historical cohort study

Yoo

Suh

et al. 2020

The Prostate

View full text Add to dashboard Cite

show abstract

“…A recent meta‐analysis reported that a low HDL‐C level was the most powerful variable associated with BPH amongst MetS‐related variables , which is in agreement with our present study results. Moreover, increasing HDL‐C levels has been reported to reduce prostate size and improve LUTS . These findings suggest that maintaining high HDL‐C levels could be a particularly important preventive strategy that should be considered from a young age.…”

Section: Discussionmentioning

confidence: 86%

The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men

Yoo

Park

et al. 2018

BJU International

View full text Add to dashboard Cite

show abstract

“…Statins reduce PSA levels by 4–13% [29, 30], and use of these medications has been inversely associated with benign prostatic enlargement and lower urinary tract symptoms [31, 32], suggesting that statins also directly influence prostate biology. Inflammation has been suggested as one potential mechanism contributing to these effects [33–35]. Indeed, results from clinical trials have shown that statins have systemic anti-inflammatory properties over and above their cholesterol-lowering function [10, 11], and studies have also shown tissue-specific anti-inflammatory effects of statins, in adipose tissue [36] and in the vascular wall [37].…”

Section: Discussionmentioning

confidence: 99%

Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial

Allott

Howard

Vidal

et al. 2017

Cancer Prevention Research

View full text Add to dashboard Cite

Statin use is associated with lower advanced prostate cancer risk. In addition to cholesterol-lowering, statins have systemic anti-inflammatory properties. However, their effect on histological prostate inflammation is not well understood, particularly among men at increased prostate cancer risk but with a negative prostate biopsy. We examined associations between serum lipid levels, statin use and histological prostate inflammation using data from 6,655 men with a negative baseline prostate biopsy in the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Statin use and lipid levels [total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides] were assessed at baseline. Inflammation was assessed by central review. Logistic regression was used to examine the effects of lipids and statin use on presence and extent of chronic and acute prostate inflammation [none, moderate (<20%), severe (≥20% biopsy cores)]. Chronic and acute inflammation affected 77% and 15% of men, respectively. Men with high HDL (≥60 vs. <40 mg/dl) had reduced presence of acute inflammation (OR 0.79; 95%CI 0.63–0.99), and were less likely to have severe acute inflammation (OR 0.66; 95%CI 0.45–0.97), but there were no other associations between lipids and inflammation. Statin users had reduced presence of chronic inflammation (OR 0.81; 95%CI 0.69–0.95), and were less likely to have severe chronic (OR 0.80; 95%CI 0.68–0.95) and severe acute inflammation (OR 0.73; 95%CI 0.53–1.00), relative to non-users. Given the possible role for inflammation in prostate cancer, the inverse association between statins and prostate inflammation suggests a mechanism linking statins with lower advanced prostate cancer risk.

show abstract

The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome

Abstract: Simvastatin and atorvastatin significantly reduced PV, improved lower urinary tract symptoms, and slowed the clinical progression of BPH possibly by lowering cholesterol and anti-inflammatory factors.

Cited by 32 publications

References 28 publications

Optimal high‐density lipoprotein cholesterol level for decreasing benign prostatic hyperplasia in men not taking statin medication: A historical cohort study

Optimal high‐density lipoprotein cholesterol level for decreasing benign prostatic hyperplasia in men not taking statin medication: A historical cohort study

The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men

Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial

Contact Info

Product

Resources

About